Tag: pembrolizumab
Oncology Trials Could Benefit From Increased Data on Tobacco Use
By Leah Lawrence
Posted: June 24, 2020
As part of its declaration on tobacco cessation after cancer diagnosis, the IASLC recommended that smoking status, both initially...
Single-Agent Pembrolizumab Active Against STK11– and KEAP1– Mutated NSCLC According to...
By Kara Nyberg, PhD
Posted: June 24, 2020
Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold...
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD
Posted: April 16, 2020
After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life...
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC...
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD
Posted: April 16, 2020
Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of...
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With...
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on...
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab
By Suresh Ramalingam, MD
Posted: December 11, 2019
IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced...
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019
Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking...
2019 IASLC World Conference on Lung Cancer Updates
Posted: November 12, 2019
More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and...
